Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7138392 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2017
(7 years ago) | |
US5998402 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2019
(5 years ago) | |
US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8815934 | WYETH PHARMS | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations |
May, 2019
(4 years ago) | |
US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(15 days from now) |
Duavee is owned by Wyeth Pharms.
Duavee contains Bazedoxifene Acetate; Estrogens, Conjugated.
Duavee has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Duavee are:
Duavee was authorised for market use on 03 October, 2013.
Duavee is available in tablet;oral dosage forms.
Duavee can be used as treatment of moderate to severe vasomotor symptoms associated with menopause, prevention of postmenopausal osteoporosis.
Drug patent challenges can be filed against Duavee from 13 October, 2017.
The generics of Duavee are possible to be released after 10 March, 2027.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 13, 2018 |
New Product(NP) | Oct 03, 2016 |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
NCE-1 date: 13 October, 2017
Market Authorisation Date: 03 October, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause; Prevention of postmenopausal osteoporosis
Dosage: TABLET;ORAL